Jiangbo Pharmaceuticals to Present at Brean Murray, Carret 2009 China Growth Conference

Friday, November 13, 2009 General News J E 4
LAIYANG, China, Nov. 12 JiangboPharmaceuticals, Inc. (OTC Bulletin Board: JGBO) (the "Company" or "Jiangbo"),a pharmaceutical company with its principal operations in China, todayannounced that the Company's management will present at the upcoming BreanMurray, Carret & Co. 2009 China Growth Conference.

The Brean Murray, Carret & Co. 2009 China Growth Conference is atwo-day conference (November 19-20, 2009) that consists of 25-minutepresentation slots followed by 10-minutes of open floor Q&A sessions withinstitutional investors. Senior management of presenting companies, industryexperts, and institutional investors will receive a unique and comprehensiveview of China from a global perspective. Jiangbo's management will beavailable for 1x1 meetings before and after the Company's presentation.

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals is engaged in the research, development,production, marketing and sales of pharmaceutical products in China. TheCompany's operations are located in Eastern China in an Economic DevelopmentZone in Laiyang City, Shandong Province. Jiangbo produces both western andChinese herbal-based medical drugs in tablet, capsule, granule, syrup andelectuary (sticky syrup) form. For additional information, please visit theCompany's website ( ).

Safe Harbor Statement

Certain statements in this press release that are not historical facts are"forward-looking statements" within the meaning of the Private SecuritiesLitigation Reform Act of 1995. Such statements are not guarantees of futureperformance and are subject to risks and uncertainties that could cause theCompany's actual results and financial position to differ materially fromthose included within the forward-looking statements. Forward-lookingstatements involve risks and uncertainties. Actual results may differmaterially from anticipated or predicted results, and reported results shouldnot be considered as an indication of future performance. The potential risksand uncertainties include, among others, the Company's ability to obtain rawmaterials needed in manufacturing, the continuing employment of key employees,the failure risks inherent in testing any new drug, the possibility thatregulatory approvals may be delayed or become unavailable, patent or licensingconcerns that may include litigation, direct competition from othermanufacturers and product obsolescence. More information about the potentialfactors that could affect the Company's business and financial results isincluded in the Company's filings, available via the United States Securitiesand Exchange Commission.Date: November 19, 2009 Time: 10:40 a.m. - 11:15 a.m. EST Presenter: Ms. Elsa Sung, CFO Location: The Millennium Broadway Hotel New York, NY

SOURCE Jiangbo Pharmaceuticals, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
VerticalResponse, Inc. Surveys 831 Small Businesse...
Centerplate and the Capital Improvement Board Inve...